Construction And Identification Of Recombinant Adenoviral Vector Containing Cox-2L Promoter And SSTR₂ Gene

Pancreatic cancer is a kind of neoplasm with high malignancy and become one of main risk factor to harm human health .It is the fourth leading cause of death in Western countries. Data from IARC show that : 217000 cases with the cancer was found in 2000, 213000 of them died in the same year. The 5 year-survival rate of the cancer is only 5-9%. Up to now, surgical therapy is still main method to treat it . Unfortunately, 70%-75% of the cases lost their chance to be treated by operation because of local infiltration and distant metastasis of the cancer cells. Although traditional chemotherapy and radiotherapy can prolong survival time for the patients, the effects are very limited. So new approaches are needed urgently to improve survival rate. It is gene therapy that guide physicians to a new road to conquer the disease. Gene therapy for the cancer include tumor suppressor gene substitution therapy; antisense gene therapy; immune gene therapy and receptor gene therapy. In receptor gene therapy study, researchers found that somatostatin receptor typeâ…¡(SSTR2) closely related to pancreatic cancer . Somatostatin could inhibit growth of those pancreatic cancer cell lines with SSTR2 expression while has no inhibition effects on those ones that did not express SSTR2 . But when SSTR2 gene was transferred into and expressed SSTR2 in the latter ones, cell growth inhibition effects can be seen as the former ones. So SSTR2 gene was considered as specific receptor gene for pancreatic cancer and was widely researched. In fact, SSTR2 was confirmed seldom to be found in most pancreatic cancer. A special vector should be used to transfer SSTR2 gene into target cancer cell to make it express SSTR2.